JMP Securities Reiterates Market Outperform on Vor Biopharma, Maintains $12 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Vor Biopharma (NASDAQ:VOR) and maintained a $12 price target.
August 14, 2023 | 12:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vor Biopharma's stock rating has been reiterated as Market Outperform by JMP Securities, with a maintained price target of $12.
The reiteration of the Market Outperform rating and the maintained price target by JMP Securities indicates a positive outlook for Vor Biopharma. This could potentially lead to an increase in investor confidence and a positive impact on the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100